Mark Edward Zak

This inventor holds 23 USPTO granted patents and 16 published patent applications, plus 2 CIPO patents and 16 EPO patents, primarily in JAK Kinase Inhibitors. Top assignees: Genentech, Inc., Forma Tm, LLC, Hoffmann-La Roche Inc.. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mark Edward Zak. Retrieved from https://idiyas.com/inventor/mark-edward-zak

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 23 (Patent Applications = 16)

% Patents Active = 87.0

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 16 (Patent Applications = 19)

Average Co-Inventor Count = 5.3

ph-index = 5

Forward Citations = 113(Granted Patents)

Location History:

Sun Valley, CA (US) (2012)
San Mateo, CA (US) (2011 - 2017)
South San Francsico, CA (US) (2020)
South San Francisco, CA (US) (2016 - 2022)
San Carlos, CA (US) (2019 - 2023)
Davidsonville, MD (US) (2023)

Company Filing History:

Hoffmann-La Roche Inc.

6. 2 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 2011-2026

Loading Chart...

Areas of Expertise:

JAK Kinases

Pyrazolopyrimidine

Therapeutic Compounds

Compositions

Inhibitors

Amido Derivatives

Triazolopyridine

Sulfoxide Derivatives

Tankyrase

Angular Position Sensor

5-Anilinoimidazopyridines

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12528812 - Pyrazolopyrimidine aryl ether inhibitors of JAK kinases and uses thereof (2026-01-20),

2. 12247032 - Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of JAK kinases (2025-03-11),

3. 11795170 - Therapeutic compounds, compositions and methods of use thereof (2023-10-24),

4. 11731943 - Therapeutic compounds, compositions and methods of use thereof (2023-08-22),

5. 11649241 - Pyrazolochlorophenyl compounds, compositions and methods of use thereof (2023-05-16),

6. 11485745 - Amido spirocyclic amide and sulfonamide derivatives (2022-11-01),

7. 11453671 - Pyrazolopyrimidine inhibitors of JAK kinases and uses thereof (2022-09-27),

8. 11155557 - Pyrazolopyrimidine compounds and methods of use thereof (2021-10-26),

9. 10730889 - Amido spirocyclic amide and sulfonamide derivatives (2020-08-04),

10. 10696692 - Amido-benzyl sulfone and sulfoxide derivates (2020-06-30),

11. 10307426 - Therapeutic compounds and compositions, and methods of use thereof (2019-06-04),

12. 10189836 - Therapeutic compounds, compositions and methods of use thereof (2019-01-29),

13. 9873709 - Triazolopyridine compounds, compositions and methods of use thereof (2018-01-23),

14. 9822129 - Amido spirocyclic amide and sulfonamide derivatives (2017-11-21),

15. 9604984 - 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof (2017-03-28),

Title: Mark Edward Zak: Innovator in JAK Kinase Inhibition

Introduction

Mark Edward Zak, located in San Mateo, CA, is a notable inventor with an impressive portfolio boasting 21 patents. His work primarily revolves around therapeutic compounds designed to inhibit Janus kinases (JAK), a crucial area in pharmaceutical innovation focused on treating various diseases.

Latest Patents

Among his latest contributions, Zak has developed substituted pyrazolo[1,5-a]pyrimidines, detailed in his patents as compounds that serve as effective JAK kinase inhibitors. These compounds are described with a specific formula, including salts and forms that enhance their utility in pharmaceutical compositions. His innovative methods also cover the treatment and management of conditions responsive to JAK inhibition, showcasing his commitment to advancing healthcare solutions.

Career Highlights

Mark Zak has gained valuable experience working with leading companies in the biotechnology sector, including Genentech, Inc. and Forma Therapeutics, LLC. His roles at these organizations have allowed him to push the boundaries of research and development in genetic modulation and drug design, emphasizing the importance of structures that inhibit kinase activity.

Collaborations

Throughout his career, Zak has collaborated with distinguished professionals, including Yun-Xing Cheng and Po-Wai Yuen. These partnerships have fostered an environment of innovation, contributing to significant advancements in therapeutic strategies and compound development.

Conclusion

Mark Edward Zak stands out as a leading inventor in the realm of JAK kinase inhibitors. His numerous patents reflect a deep understanding of pharmacology and a dedication to creating effective therapeutic solutions. As he continues to innovate, the impact of his work is likely to resonate within the pharmaceutical industry and beyond.

Profile summary based on public USPTO records.